KALA

insider transactions

Kala Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-1.1M

0 buy · 1.1M sell

Net value · 365d

-$1.4M

$0 in · $1.4M out

Sentiment · 365d

Net selling

0% buying · 100% selling

Open-market trades · 365d

0 buy · 1.1M sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Other·J
Dec 18, 25

Lazar David E. KEY

Chief Executive Officer

—

368.6K sh
Grant·A
Nov 24, 25

Lazar David E. KEY

Chief Executive Officer

—

900.0K sh

Own New
Sell·S
Oct 23, 25

Iwicki Mark T

Director

$125.5K

154.9K sh · $0.81

Own -60%
Sell·S
Oct 23, 25

Reumuth Mary KEY

CHIEF FINANCIAL OFFICER

$793

967 sh · $0.82

Own -3%
Sell·S
Oct 22, 25

Brazzell Romulus K

SEE REMARKS

$38.8K

46.7K sh · $0.83

Own -57%
Sell·S
Oct 22, 25

Kharabi Darius

CHIEF BUSINESS OFFICER

$17.3K

20.8K sh · $0.83

Own -33%
Sell·S
Oct 22, 25

Bazemore Todd

Director

$39.6K

47.8K sh · $0.83

Own -57%
Sell·S
Oct 22, 25

Reumuth Mary KEY

CHIEF FINANCIAL OFFICER

$26.8K

32.2K sh · $0.83

Own -52%
Sell·S
Oct 1, 25

BAKER JULIAN

Other

$69.9K

50.6K sh · $1.38

Own -52%
Sell·S
Oct 1, 25

BAKER JULIAN

Other

$638.9K

463.0K sh · $1.38

Own -52%
Sell·S
Sep 30, 25

BAKER JULIAN

Other

$312.7K

195.4K sh · $1.60

Own -18%
Sell·S
Sep 30, 25

BAKER JULIAN

Other

$34.2K

21.4K sh · $1.60

Own -18%
Grant·A
Aug 29, 25

Bazemore Todd

SEE REMARKS

$0

180.0K sh

Own New
Sell·S
Jun 24, 25

Bazemore Todd

SEE REMARKS

$16.3K

4.1K sh · $4.01

Own -5%
Sell·S
Jun 24, 25

Kharabi Darius

CHIEF BUSINESS OFFICER

$18.1K

4.5K sh · $4.01

Own -7%
Sell·S
Jun 24, 25

Brazzell Romulus K

SEE REMARKS

$21.1K

5.3K sh · $4.01

Own -6%
Sell·S
Jun 24, 25

Iwicki Mark T

Director

$53.0K

13.2K sh · $4.01

Own -5%
Sell·S
Jun 24, 25

Reumuth Mary KEY

CHIEF FINANCIAL OFFICER

$14.6K

3.6K sh · $4.01

Own -6%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Dec 18, 2025	Lazar David E. KEY	Chief Executive Officer	Other J	368.6K	—	—	—
Nov 24, 2025	Lazar David E. KEY	Chief Executive Officer	Grant A	900.0K	New	—	—
Oct 23, 2025	Iwicki Mark T	Director	Sell S	154.9K	-60%	$0.81	$125.5K
Oct 23, 2025	Reumuth Mary KEY	CHIEF FINANCIAL OFFICER	Sell S	967	-3%	$0.82	$793
Oct 22, 2025	Brazzell Romulus K	SEE REMARKS	Sell S	46.7K	-57%	$0.83	$38.8K
Oct 22, 2025	Kharabi Darius	CHIEF BUSINESS OFFICER	Sell S	20.8K	-33%	$0.83	$17.3K
Oct 22, 2025	Bazemore Todd	Director	Sell S	47.8K	-57%	$0.83	$39.6K
Oct 22, 2025	Reumuth Mary KEY	CHIEF FINANCIAL OFFICER	Sell S	32.2K	-52%	$0.83	$26.8K
Oct 1, 2025	BAKER JULIAN	Other	Sell S	50.6K	-52%	$1.38	$69.9K
Oct 1, 2025	BAKER JULIAN	Other	Sell S	463.0K	-52%	$1.38	$638.9K
Sep 30, 2025	BAKER JULIAN	Other	Sell S	195.4K	-18%	$1.60	$312.7K
Sep 30, 2025	BAKER JULIAN	Other	Sell S	21.4K	-18%	$1.60	$34.2K
Aug 29, 2025	Bazemore Todd	SEE REMARKS	Grant A	180.0K	New	—	$0
Jun 24, 2025	Bazemore Todd	SEE REMARKS	Sell S	4.1K	-5%	$4.01	$16.3K
Jun 24, 2025	Kharabi Darius	CHIEF BUSINESS OFFICER	Sell S	4.5K	-7%	$4.01	$18.1K
Jun 24, 2025	Brazzell Romulus K	SEE REMARKS	Sell S	5.3K	-6%	$4.01	$21.1K
Jun 24, 2025	Iwicki Mark T	Director	Sell S	13.2K	-5%	$4.01	$53.0K
Jun 24, 2025	Reumuth Mary KEY	CHIEF FINANCIAL OFFICER	Sell S	3.6K	-6%	$4.01	$14.6K

About KALA insider trading

This page tracks insider transactions for Kala Pharmaceuticals, Inc. (KALA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.